The CRI Clinical Innovator funding program from the Cancer Research Institute supports novel clinical studies that address areas of high unmet need in cancer and seek mechanistic insights into clinical response with a goal of predictive biomarker discovery. The program supports clinician-scientists aiming to launch innovative phase I/II or phase II clinical studies using novel immunotherapies. Applicants may be based at non-profit research institutions worldwide. Applicants may apply for up to 1 million USD.
Letters of intent are due December 1, 2023. Full invited applications are due on May 1, 2024.
May 1, 2024